Related Experiment Video

Updated: Apr 30, 2026

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

A Murine Model of Stent Implantation in the Carotid Artery for the Study of Restenosis

Published on: May 14, 2013

Sex Differences in Prognostic Implications of CYP2C19 Genotype After Drug-Eluting Stent Implantation

Soo-Jin Kim¹, Ae-Young Her², Hyung Joon Joo³

¹Division of Cardiology, Department of Internal Medicine Kosin University College of Medicine Busan Korea.

Journal of the American Heart Association

|April 28, 2026

Abstract

Background:

Dual-antiplatelet therapy is standard after percutaneous coronary intervention, but clopidogrel responsiveness varies with CYP2C19 loss-of-function alleles. Whether the genotype conveys different prognostic significance between sexes is uncertain.

Methods:

We analyzed 4630 East-Asian patients with acute coronary syndrome in the PTRG-DES (Platelet Function- and Genotype-Related Long-Term Prognosis in Drug-Eluting Stent-Treated Patients With Coronary Artery Disease) consortium with available CYP2C19 genotyping. Patients were classified as rapid/normal metabolizers versus intermediate/poor metabolizers. The primary end point was cardiac death, myocardial infarction, or definite stent thrombosis within 5 years.

Results:

Among 4630 patients with acute coronary syndrome, 1708 (36.9%) were women. The prevalence of intermediate/poor metabolizer phenotypes was similar in women (61.8%) and men (62.5%). After multivariable adjustment for clinical, laboratory, and procedural confounders, intermediate/poor metabolizer carriers had a significantly higher risk of the 5-year primary outcome in men compared with rapid/normal metabolizer carriers (adjusted hazard ratio [HR], 3.27 [95% CI, 1.58-6.74]; P=0.001). In contrast, no significant association was observed in women (adjusted HR, 1.21 [95% CI, 0.58-2.52]; P = 0.615). Intermediate/poor metabolizer status was also associated with a higher risk of 5-year cardiac death in men only (adjusted HR, 7.01 [95% CI, 2.01-24.48]; P=0.002). Significant interactions between sex and CYP2C19 metabolizer status were observed for both the primary outcome (P for interaction=0.034) and cardiac death (P for interaction=0.049).

Conclusions:

CYP2C19 loss-of-function allele status was a significant predictor of long-term adverse cardiovascular outcomes in men but not in women, suggesting a sex-specific prognostic difference in patients with acute coronary syndrome undergoing percutaneous coronary intervention.

Registration:

URL: https://www.clinicaltrials.gov; Unique identifier: NCT04734028.

Keywords:

CYP2C19 genotype coronary artery disease drug‐eluting stent female sex

More Related Videos

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Signal Acquisition, Score Interpretation, and Economics of a Non-Invasive Point-of-Care Test for Coronary Artery Disease

Published on: August 9, 2024

Related Concept Videos

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Pharmacogenetic Phenotypes: Alterations in Pharmacokinetics, Drug Targets and Biologic Milieu

Genetic variations significantly influence drug response through pharmacokinetics, receptor interactions, and biologic milieu modifications. Pharmacokinetic alterations impact drug metabolism and clearance, affecting efficacy and toxicity. Variants in drug-metabolizing enzymes, such as CYP2C9 and CYP2C19, alter drug activation and elimination. For example, CYP2C9 loss-of-function variants require lower warfarin doses to prevent excessive bleeding, while CYP2C19 variants reduce clopidogrel...

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Pharmacogenetics of Phase I Enzymes: Cytochrome P450 Isozymes

Cytochrome P450 (CYP450) enzymes are a superfamily of heme-containing monooxygenases that play a pivotal role in Phase I drug metabolism by catalyzing oxidation and reduction reactions.These enzymes transform lipophilic xenobiotics into more hydrophilic metabolites, facilitating subsequent Phase II conjugation and eventual excretion. The CYP450 family is classified into families (e.g., CYP1–CYP3) and subfamilies (e.g., CYP2A, CYP2C), based on amino acid sequence homology.CYP450...

Pharmacogenetics of Drug Metabolism: Overview

Pharmacogenetics of Drug Metabolism: Overview

Genetic polymorphism in drug metabolism is crucial to the inter-individual variability observed in drug responses. Drug metabolism primarily involves the chemical modification of drugs and other xenobiotics to enhance their elimination by increasing their polarity. Two main classes of enzymes mediate this biotransformation process: Phase I enzymes, primarily cytochrome P450s, catalyze oxidation and reduction reactions, while other enzymes, such as esterases, mediate hydrolysis, and Phase II...

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Pharmacogenetics of Drug Targets: β₂-Adrenergic Receptors, Apo E, Thymidylate Synthase

Genetic polymorphisms in drug targets have emerged as critical determinants of interindividual variability in drug response and toxicity. Pharmacogenomic investigations increasingly focus on identifying these variations to personalize and optimize therapeutic interventions. A drug target may be a receptor, enzyme, or signaling protein involved in pharmacologic responses or disease-related pathways. While early pharmacogenetic studies focused primarily on drug metabolism, current research...

Pharmacogenomics: Identification of New Drug Targets

Pharmacogenomics: Identification of New Drug Targets

Advances in genomics have profoundly influenced drug discovery by increasing both the speed and accuracy of pharmaceutical development. Pharmacogenomics, which examines how genetic variation influences drug response, facilitates the identification of novel therapeutic targets and enables patient stratification for personalized treatment. These strategies contribute to improved drug efficacy, minimized adverse effects, and more efficient clinical trial design.Mapping genetic differences...

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

Pharmacogenetics of Drug Transporters: P-Glycoprotein and Solute Carrier Transporters

The pharmacogenetics of drug transporters is increasingly recognized as a critical factor influencing interindividual variability in drug absorption, distribution, and elimination. These membrane-bound proteins regulate drugs' movement across cellular barriers by actively pumping them out (efflux) or facilitating their uptake (influx). Among the major transporter families, ATP-binding cassette (ABC) and solute carrier (SLC) transporters play particularly prominent roles. Genetic polymorphisms...

Articles linked to this work by shared authors, journal, and citation graph.

Clopidogrel or Dual Antiplatelet Therapy in High-Ischemic-Risk Patients.

The New England journal of medicine·2026

Drug-Coated Balloon-Based Versus Drug-Eluting Stent-Only Strategy in Stable Angina and Acute Coronary Syndrome: A Propensity-Score Overlap-Weighted Analysis.

Journal of clinical medicine·2026

Real-World Evidence on Short-Term Weight Changes Following Methylphenidate Use in Pediatric Population: A Retrospective Study Using Common Data Model.

Clinical and translational science·2026

Serial Optical Coherence Tomography Assessment of Plaque Phenotype Stabilization after Paclitaxel-Coated Balloon Treatment in De Novo Coronary Lesions.

Yonsei medical journal·2026

Lipoprotein(a), Oxidized Phospholipids and Tensile Clot Strength Measured by Thromboelastography in Patients Undergoing Percutaneous Intervention.

Arteriosclerosis, thrombosis, and vascular biology·2026

Concordance Between Randomized Controlled and Real-World Evidence for Distal Radial Access: A Structured Comparison of the DISCO RADIAL Trial and KODRA Study.

Catheterization and cardiovascular interventions : official journal of the Society for Cardiac Angiography & Interventions·2026

See all related articles